JP2017536369A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536369A5
JP2017536369A5 JP2017527260A JP2017527260A JP2017536369A5 JP 2017536369 A5 JP2017536369 A5 JP 2017536369A5 JP 2017527260 A JP2017527260 A JP 2017527260A JP 2017527260 A JP2017527260 A JP 2017527260A JP 2017536369 A5 JP2017536369 A5 JP 2017536369A5
Authority
JP
Japan
Prior art keywords
nrc
compound according
sulfur
nitrogen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017527260A
Other languages
English (en)
Japanese (ja)
Other versions
JP6787892B2 (ja
JP2017536369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061463 external-priority patent/WO2016081679A1/en
Publication of JP2017536369A publication Critical patent/JP2017536369A/ja
Publication of JP2017536369A5 publication Critical patent/JP2017536369A5/ja
Application granted granted Critical
Publication of JP6787892B2 publication Critical patent/JP6787892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017527260A 2014-11-20 2015-11-19 Irakインヒビターとしてのヘテロアリール化合物及びその使用 Active JP6787892B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082231P 2014-11-20 2014-11-20
US62/082,231 2014-11-20
PCT/US2015/061463 WO2016081679A1 (en) 2014-11-20 2015-11-19 Heteroaryl compounds as irak inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2017536369A JP2017536369A (ja) 2017-12-07
JP2017536369A5 true JP2017536369A5 (2) 2018-12-20
JP6787892B2 JP6787892B2 (ja) 2020-11-18

Family

ID=54705914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017527260A Active JP6787892B2 (ja) 2014-11-20 2015-11-19 Irakインヒビターとしてのヘテロアリール化合物及びその使用

Country Status (24)

Country Link
US (2) US9790221B2 (2)
EP (1) EP3221306B1 (2)
JP (1) JP6787892B2 (2)
KR (2) KR102683518B1 (2)
CN (1) CN107108561B (2)
AR (1) AR103138A1 (2)
AU (1) AU2015349899B9 (2)
CA (1) CA2964982C (2)
DK (1) DK3221306T3 (2)
ES (1) ES2772133T3 (2)
HR (1) HRP20200179T1 (2)
HU (1) HUE047586T2 (2)
IL (1) IL252346B (2)
LT (1) LT3221306T (2)
MX (1) MX375625B (2)
NZ (1) NZ730728A (2)
PL (1) PL3221306T3 (2)
PT (1) PT3221306T (2)
RS (1) RS59974B1 (2)
RU (1) RU2743718C2 (2)
SG (1) SG11201702741SA (2)
SI (1) SI3221306T1 (2)
WO (1) WO2016081679A1 (2)
ZA (1) ZA201702402B (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3286181T (lt) 2015-04-22 2021-04-26 Rigel Pharmaceuticals, Inc. Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
AU2017222958B2 (en) * 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP7170634B2 (ja) 2016-10-26 2022-11-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Irak阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
AU2017363313B2 (en) * 2016-11-22 2021-06-24 Dana-Farber Cancer Institute, Inc. Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
MX394556B (es) * 2017-02-01 2025-03-24 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN110831937A (zh) * 2017-05-02 2020-02-21 韩国化学研究院 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物
US20210145771A1 (en) * 2017-07-03 2021-05-20 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
CN118239937A (zh) * 2017-08-09 2024-06-25 戴纳立制药公司 化合物、组合物及方法
DK3676297T3 (da) 2017-09-01 2023-08-14 Denali Therapeutics Inc Forbindelser, sammensætninger og fremgangsmåder
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
MA54953A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PE20220970A1 (es) 2019-08-30 2022-06-10 Rigel Pharmaceuticals Inc Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
EP4320103A1 (en) * 2021-04-09 2024-02-14 Quanta Therapeutics, Inc. Pyrimidine based ras modulators and uses thereof
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
CN116514769B (zh) * 2022-01-21 2024-02-27 中国药科大学 4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
IL315677A (en) 2022-03-23 2024-11-01 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
KR20260041941A (ko) 2023-03-15 2026-03-27 콴타 테라퓨틱스, 인크. Kras 조절 인자 및 이의 용도
CN117924102A (zh) * 2024-01-23 2024-04-26 成都伊诺达博医药科技有限公司 一种微管亲和力调节激酶抑制剂中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026377A1 (en) * 2007-08-20 2009-02-26 Board Of Regents, The University Of Texas System Metal-containing polymers and uses thereof
JP5402639B2 (ja) * 2007-10-26 2014-01-29 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
HRP20160044T1 (hr) 2008-08-04 2016-02-26 Merck Patent Gmbh Novi spojevi fenilamino izonikotinamida
CA2757671A1 (en) * 2009-04-03 2010-10-07 Cellzome Ag Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
JP2011098948A (ja) * 2009-06-25 2011-05-19 Yamagata Promotional Organization For Industrial Technology ビピリジン誘導体及びそれを含む有機エレクトロルミネッセンス素子
WO2011084402A1 (en) * 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
CN110003219A (zh) * 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
WO2013134415A1 (en) * 2012-03-07 2013-09-12 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
US20150041789A1 (en) * 2012-03-22 2015-02-12 Konica Minolta, Inc. Transparent electrode, electronic device, and organic electroluminescent element
JP6189434B2 (ja) 2012-07-10 2017-08-30 アレス トレーディング ソシエテ アノニム ピリミジンピラゾリル誘導体
EP3092225B1 (en) * 2014-01-09 2019-02-27 Merck Patent GmbH Pyrimidine pyrazolyl derivatives and their use as irak inhibitors

Similar Documents

Publication Publication Date Title
JP2017536369A5 (2)
JP2018537501A5 (2)
RU2017120274A (ru) Гетероарильные соединения в качестве ингибиторов irak и их применения
JP2019527718A5 (2)
JP2018505166A5 (2)
RU2019105719A (ru) Антагонисты tlr7/8 и их применение
RU2378263C2 (ru) Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
JP2022516469A5 (2)
JP2012508252A5 (2)
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
JP2021533125A5 (2)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
JP2009511490A5 (2)
JP2009515988A5 (2)
JP2015518903A5 (2)
JP2020537671A5 (2)
JP2017509586A5 (2)
RU2018113451A (ru) Гетероарильные соединения в качестве ингибиторов irak и их применение
JP2017511357A5 (2)
JP2017538689A5 (2)
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
RU2020115596A (ru) ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ
JP2018520455A5 (2)
JP2010528021A5 (2)
RU2017130761A (ru) Макроциклы пиридазинона в качестве ингибиторов irak-киназы и их применения